drugset / Trial / NCT02178722

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

NCT02178722

Phase 1/2 Completed 444 enrolled Incyte Corporation Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.

Timeline

Start
2014-07-17
Primary completion
2018-11-26
Completion
2020-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Epacadostat Small molecule 25 mg
Subject Pembrolizumab Monoclonal antibody